[1]刘璐璐,章浙伟,杨永波,等.CT灌注参数动脉增强分数值在评估肝癌TACE术后疗效中的初步研究 [J].介入放射学杂志,2017,(11):988-992.
　LIU Lulu,ZHANG Zhewei,YANG Yongbo,et al.Application of quantitative arterial enhancement fraction of multiphase perfusion CT imaging in evaluating the curative effect of transcatheter arterial chemoembolization for hepatocellular carcinoma[J].journal interventional radiology,2017,(11):988-992.
点击复制

CT灌注参数动脉增强分数值在评估肝癌TACE术后疗效中的初步研究


()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年11期
页码:
988-992
栏目:
肿瘤介入
出版日期:
2017-11-25

文章信息/Info

Title:
Application of quantitative arterial enhancement fraction of multiphase perfusion CT imaging in evaluating the curative effect of transcatheter arterial chemoembolization for hepatocellular carcinoma
作者:
刘璐璐;  章浙伟;  杨永波;  范林音;  邵国良;  庞佩佩
Author(s):
LIU Lulu;  ZHANG Zhewei;  YANG Yongbo;  FAN Linyin;  SHAO Guoliang;  PANG Peipei
Department of Radiology， Zhejiang Provincial Cancer Hospital， Hangzhou， Zhejiang Province 310022， China
关键词:
【关键词】 肝细胞肝癌;  CT灌注成像;  动脉增强分数;  经导管动脉化疗栓塞术
文献标志码:
A
摘要:
【摘要】 目的 探讨常规CT三期灌注参数动脉增强分数（AEF）值在肝细胞肝癌（HCC）行TACE后疗效评价中的应用价值。方法 回顾性分析行TACE术的30例HCC患者，于术前1～3 d、术后30～40 d 分别行常规CT三期灌注扫描，应用CT Kinetics软件计算AEF参数值。AEF值为（动脉期CT值-平扫期CT值）/（门脉期CT值-平扫期CT值），并将结果进行统计学分析。结果 治疗有效组17例，治疗无效组13例。有效组术后AEF为（0.351±0.090），无效组为（0.438±0.050），差异有统计学意义（P<0.05）。以术后AEF值0.392为临界值预测TACE术后疗效，灵敏度和特异度分别为86.7%和73.2%，曲线下面积为0.876（P<0.001）。结论 常规CT三期灌注参数AEF能定量反映肝癌TACE前后的血流动力学变化，有助于TACE 疗效的早期评价，且不增加格外的辐射剂量。

参考文献/References:

［1］ Tsurusaki M， Murakami T. Surgical and locoregional therapy of HCC： TACE［J］. Liver Cancer， 2015， 4： 165- 175.
［2］ Jeong SO， Kim EB， Jeong SW， et al. Predictive factors for complete response and recurrence after transarterial chemoembo- lization in hepatocellular carcinoma［J］. Gut Liver， 2017， 11： 409- 416.
［3］ Ichikawa T， Machida N， Sasaki H， et al. Early prediction of the outcome using tumor markers and mRECIST in unresectable hepatocellular carcinoma patients who underwent transarterial chemoembolization［J］. Oncology， 2016， 91： 317- 330.
［4］ Sobhani F， Xu C， Murano E， et al. Hypo- vascular liver metastases treated with transarterial chemoembolization： assessment of early response by volumetric contrast- enhanced and diffusion- weighted magnetic resonance imaging［J］. Transl Oncol， 2016， 9： 287- 294.
［5］ Boas FE， Kamaya A， Do B， et al. Classification of hypervascular liver lesions based on hepatic artery and portal vein blood supply coefficients calculated from triphasic CT scans［J］. J Digit Imaging， 2015， 28： 213- 223.
［6］ 迟秀婷， 沈加林， 程杰军， 等． CT灌注成像对评估12例5 cm以下肝癌介入治疗疗效［J］． 介入放射学杂志， 2014， 23： 772- 776．
［7］ Ogul H， Kantarc1 M， Genc B， et al. Perfusion CT imaging of the liver： review of clinical applications［J］. Diagn Interv Radiol， 2014， 20： 379- 389.
［8］ Lee DH， Lee JM， Klotz E， et al. Multiphasic dynamic computed tomography evaluation of liver tissue perfusion characteristics using the dual maximum slope model in patients with cirrhosis and hepatocellular carcinoma： a feasibility study［J］. Invest Radiol， 2016， 51： 430- 434.
［9］ Kang SE， Lee JM， Klotz E， et al. Quantitative color mapping of the arterial enhancement fraction in patients with diffuse liver disease［J］. AJR Am J Roentgenol， 2011， 197： 876- 883.
［10］ Choi SJ， Kim J， Kim HS， et al. Parametric response mapping of dynamic CT： enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization［J］. Abdom Radiol （NY）， 2017， 42： 1871- 1879.
［11］ Kim KW， Lee JM， Klotz E， et al. Quantitative CT color mapping of the arterial enhancement fraction of the liver to detect hepatocellular carcinoma［J］. Radiology， 2009， 250： 425- 434.
［12］ Joo I， Lee JM， Kim KW， et al. Liver metastases on quantitative color mapping of the arterial enhancement fraction from multiphasic CT scans： evaluation of the hemodynamic features and correlation with the chemotherapy response［J］. Eur J Radiol， 2011， 80： e278- e283.
［13］ Kim KW， Lee JM， Kim JH， et al. CT color mapping of the arterial enhancement fraction of VX2 carcinoma implanted in rabbit liver： comparison with perfusion CT［J］. AJR Am J Roentgenol， 2011， 196： 102- 108.
［14］ Lee DH， Lee JM， Klotz E， et al. Detection of recurrent hepatocellular carcinoma in cirrhotic liver after transcatheter arterial chemoembolization： value of quantitative color mapping of the arterial enhancement fraction of the liver［J］. Korean J Radiol， 2013， 14： 51- 60.

相似文献/References:

[1]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
　YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history： initial experience in seven cases[J].journal interventional radiology,2014,(11):805.
[2]刘 丽,陈 波,吴垠垠,等. CT灌注成像评价抗血管生成药物不同给药方式的疗效[J].介入放射学杂志,2014,(02):136.
　LIU Li,CHEN Bo,WU Yin? yin,et al.Application of CT perfusion imaging in evaluating the efficacy of antiangiogenic drugs via different administration routes[J].journal interventional radiology,2014,(11):136.
[3]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
　XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib： initial experience in 23 cases[J].journal interventional radiology,2014,(11):449.
[4]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
　ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma： analysis of the prognosis and survival[J].journal interventional radiology,2014,(11):435.
[5]王 龙,张 勇,王亚运,等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta 分析[J].介入放射学杂志,2018,27(05):419.
　WANG Long,ZHANG Yong,WANG Yayun,et al.125I seed implantation combined with TACE for the treatment of HCC complicated by portal vein tumor thrombus： a meta- analysis of its clinical effectiveness and safety[J].journal interventional radiology,2018,27(11):419.
[6]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
　YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure： report of three cases[J].journal interventional radiology,2016,(11):381.
[7]许 贇,沈 强,王 能,等.微波消融治疗＞70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
　XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(11):332.
[8]史博,李智岗,李亚洲,等.兔VX2肝转移瘤影像学表现与病理结构对照研究[J].介入放射学杂志,2016,(07):610.
　SHI Bo,LI Zhi-gang,LI Ya-zhou,et al.A comparative study of the imaging findings and pathological structures of VX2 liver metastasesin experimental rabbits [J].journal interventional radiology,2016,(11):610.
[9]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
　WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC： initial results in 7 patients[J].journal interventional radiology,2017,(11):161.
[10]王 燕,王茂强,段 峰.索拉非尼治疗中晚期肝癌预后因素分析[J].介入放射学杂志,2017,(03):258.
　WANG Yan,WANG Maoqiang,DUAN Feng.Prognostic factor analysis of moderate- advanced hepatocellular carcinoma treated with sorafenib [J].journal interventional radiology,2017,(11):258.

备注/Memo

备注/Memo:
（收稿日期：２０１7-０5-11）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2017-11-16